Skip to main content
editorial
. 2017 Nov 14;23(42):7495–7504. doi: 10.3748/wjg.v23.i42.7495

Figure 1.

Figure 1

Current and emerging drugs for non- alcoholic fatty liver disease and their mechanism of action. PPAR: Peroxisome proliferator-activated receptor; SCD1: Stearoyl CoA desaturase-1; FXR: Farnesoid X receptor.